INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 134 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2019. The put-call ratio across all filers is 0.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $221,955 | -98.5% | 4,261 | -98.1% | 0.00% | -97.8% |
| Q2 2023 | $14,534,220 | +4112.8% | 229,536 | +2155.0% | 0.04% | +2150.0% |
| Q1 2021 | $345,000 | -13.8% | 10,179 | -60.8% | 0.00% | -33.3% |
| Q1 2020 | $400,000 | -84.3% | 26,000 | -86.8% | 0.00% | -66.7% |
| Q2 2019 | $2,555,000 | -13.7% | 196,803 | -19.0% | 0.01% | -18.2% |
| Q1 2019 | $2,960,000 | +30.1% | 243,003 | +21.6% | 0.01% | +10.0% |
| Q4 2018 | $2,276,000 | -65.3% | 199,803 | -33.9% | 0.01% | -58.3% |
| Q3 2018 | $6,561,000 | +12.8% | 302,348 | -8.1% | 0.02% | 0.0% |
| Q2 2018 | $5,814,000 | +27.4% | 329,048 | +51.8% | 0.02% | +14.3% |
| Q1 2018 | $4,563,000 | – | 216,759 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |